Trial Profile
Antiangiogenic Treatment of Advanced or Metastatic Hepatocellular Cancer (HCC) - An Open Label, Stratified, Single-arm Phase II Study of Bevacizumab and RAD001.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Oct 2013
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Everolimus (Primary)
- Indications Liver cancer
- Focus Pharmacogenomic; Therapeutic Use
- 27 Apr 2012 Actual patient number added 33 according to ClinicalTrials.gov.
- 27 Apr 2012 Actual end date changed from 1 May 2011 to Apr 2012 added as reported by ClinicalTrials.gov record.
- 28 Mar 2012 Actual end date (1 May 2011) added as reported by European Clinical Trials Database.